NRAS and melanoma: Although there have been no studies assessing NRAS as a synthetic dose lethal target in melanoma, in acute myeloid leukaemia (AML) the multitarget kinase inhibitor GNF‐7 has been reported to induce apoptosis in NRAS‐mutant but not wild‐type AML.